JAGUAR HEALTH INC (JAGX) Fundamental Analysis & Valuation

NASDAQ:JAGX • US47010C8881

Current stock price

0.416 USD
+0.02 (+4.73%)
At close:
0.4077 USD
-0.01 (-2%)
After Hours:

This JAGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. JAGX Profitability Analysis

1.1 Basic Checks

  • JAGX had negative earnings in the past year.
  • In the past year JAGX has reported a negative cash flow from operations.
  • In the past 5 years JAGX always reported negative net income.
  • In the past 5 years JAGX always reported negative operating cash flow.
JAGX Yearly Net Income VS EBIT VS OCF VS FCFJAGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -81.45%, JAGX is doing worse than 72.02% of the companies in the same industry.
  • With a Return On Equity value of -716.07%, JAGX is not doing good in the industry: 81.87% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -81.45%
ROE -716.07%
ROIC N/A
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAGX Yearly ROA, ROE, ROICJAGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

  • The Gross Margin of JAGX (81.92%) is better than 86.53% of its industry peers.
  • In the last couple of years the Gross Margin of JAGX has grown nicely.
  • The Profit Margin and Operating Margin are not available for JAGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
JAGX Yearly Profit, Operating, Gross MarginsJAGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. JAGX Health Analysis

2.1 Basic Checks

  • JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for JAGX has been reduced compared to 1 year ago.
  • JAGX has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, JAGX has an improved debt to assets ratio.
JAGX Yearly Shares OutstandingJAGX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
JAGX Yearly Total Debt VS Total AssetsJAGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -12.75, we must say that JAGX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of JAGX (-12.75) is worse than 75.65% of its industry peers.
  • JAGX has a Debt/Equity ratio of 1.36. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.36, JAGX is not doing good in the industry: 74.61% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.36
Debt/FCF N/A
Altman-Z -12.75
ROIC/WACCN/A
WACC0.8%
JAGX Yearly LT Debt VS Equity VS FCFJAGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • JAGX has a Current Ratio of 0.81. This is a bad value and indicates that JAGX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of JAGX (0.81) is worse than 86.53% of its industry peers.
  • A Quick Ratio of 0.52 indicates that JAGX may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.52, JAGX is not doing good in the industry: 87.05% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.52
JAGX Yearly Current Assets VS Current LiabilitesJAGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. JAGX Growth Analysis

3.1 Past

  • The earnings per share for JAGX have decreased strongly by -19.82% in the last year.
  • JAGX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.45%.
  • Measured over the past years, JAGX shows a quite strong growth in Revenue. The Revenue has been growing by 15.14% on average per year.
EPS 1Y (TTM)-19.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.08%
Revenue 1Y (TTM)12.45%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%-0.8%

3.2 Future

  • Based on estimates for the next years, JAGX will show a very strong growth in Earnings Per Share. The EPS will grow by 40.54% on average per year.
  • The Revenue is expected to grow by 118.46% on average over the next years. This is a very strong growth
EPS Next Y89.56%
EPS Next 2Y40.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JAGX Yearly Revenue VS EstimatesJAGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
JAGX Yearly EPS VS EstimatesJAGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 -200M -400M -600M -800M -1B

More info and screens

Find the best growth stocksShow best growing peers

1

4. JAGX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for JAGX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JAGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAGX Price Earnings VS Forward Price EarningsJAGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAGX Per share dataJAGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as JAGX's earnings are expected to grow with 40.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.54%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JAGX Dividend Analysis

5.1 Amount

  • JAGX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JAGX Fundamentals: All Metrics, Ratios and Statistics

JAGUAR HEALTH INC

NASDAQ:JAGX (3/25/2026, 4:57:56 PM)

After market: 0.4077 -0.01 (-2%)

0.416

+0.02 (+4.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-18
Earnings (Next)03-30
Inst Owners1.44%
Inst Owner Change-31.27%
Ins Owners15.22%
Ins Owner Change1.27%
Market Cap1.89M
Revenue(TTM)11.79M
Net Income(TTM)-40.29M
Analysts85.71
Price Target16.32 (3823.08%)
Short Float %10.57%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-31.14%
Min EPS beat(2)-41.08%
Max EPS beat(2)-21.2%
EPS beat(4)2
Avg EPS beat(4)11.24%
Min EPS beat(4)-41.08%
Max EPS beat(4)98.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.4%
Min Revenue beat(2)-18.98%
Max Revenue beat(2)-11.83%
Revenue beat(4)1
Avg Revenue beat(4)-11.33%
Min Revenue beat(4)-23.04%
Max Revenue beat(4)8.52%
Revenue beat(8)1
Avg Revenue beat(8)-15.72%
Revenue beat(12)4
Avg Revenue beat(12)-7.43%
Revenue beat(16)5
Avg Revenue beat(16)-7.91%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.16
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-33.58
EYN/A
EPS(NY)-5.79
Fwd EYN/A
FCF(TTM)-5.79
FCFYN/A
OCF(TTM)-5.73
OCFYN/A
SpS2.6
BVpS1.24
TBVpS-2.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -81.45%
ROE -716.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.92%
FCFM N/A
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.05%
Cap/Sales 2.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.52
Altman-Z -12.75
F-Score4
WACC0.8%
ROIC/WACCN/A
Cap/Depr(3y)32.24%
Cap/Depr(5y)19.49%
Cap/Sales(3y)5.33%
Cap/Sales(5y)3.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.08%
EPS Next Y89.56%
EPS Next 2Y40.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.45%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%-0.8%
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%
EBIT growth 1Y-9.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.22%
OCF growth 3YN/A
OCF growth 5YN/A

JAGUAR HEALTH INC / JAGX Fundamental Analysis FAQ

What is the fundamental rating for JAGX stock?

ChartMill assigns a fundamental rating of 2 / 10 to JAGX.


What is the valuation status of JAGUAR HEALTH INC (JAGX) stock?

ChartMill assigns a valuation rating of 1 / 10 to JAGUAR HEALTH INC (JAGX). This can be considered as Overvalued.


What is the profitability of JAGX stock?

JAGUAR HEALTH INC (JAGX) has a profitability rating of 1 / 10.


How financially healthy is JAGUAR HEALTH INC?

The financial health rating of JAGUAR HEALTH INC (JAGX) is 1 / 10.


What is the earnings growth outlook for JAGUAR HEALTH INC?

The Earnings per Share (EPS) of JAGUAR HEALTH INC (JAGX) is expected to grow by 89.56% in the next year.